The positive results of the first clinical trials in humans bring the hope of closing the bomb-meditor
The Annual Meeting of the American Association Diabetes last week brought us the news of the publication of the results of the first clinical essay in humans of a project on the artificial pancreas.
The Ánimas Corporation (of the Johnson and Johnson group, which also has Lifescan) is the company behind this project, together with the JDRF.
In June of last year, he received authorization for this study by the US FDA.
The minimizing hypoglycemia-hyperglycemia (HHM)
The main objective of the work was to assess the algorithm to predict the increase and decrease of glucose and if the amount of insulin released was increased according to these parameters.Now it remains to expand the sample of patients studied.
No signature configured, update it from user's profile.
That is almost impossible to say it, Roa.
Normal, a drug or a glucometer or a pump, it takes 1 year or so in "crossing the puddle", first it is approved and marketed in the US, then it comes to Europe (1 year) and then to Spain (another 2-3months).
A reliable artificial pancreas system I don't see it before 10 years ...: ((((
I would like to think that before 5 years we could have a continuous non -invasive sensor ... but I think I'm going to make mistakes.
No signature configured, update it from user's profile.
It is good that a company as powerful as Animas puts the batteries to develop the artificial pancreas project, for now it is not more than we have, in fact in the article in English, it makes the findings serve and much for future rehearsals and investigations.The novelty is that the pump supplies automatically insulin (without user programming) although I have not read effectiveness pores.Currently, Medtronic has the automatic suspension option of the insulin supply before a hypoglycemia detected by the continuous meter, which can already be considered "chlooking the loop", but there is still a long way to go on the sensor's reliability (Continuous meter) Decrease user interation, and improve accessibility. Recently, to see if I find it, that they were testing a new artificial pancreas study, this time with a sensor that combined in itself two forms of measurement that of interstitial fluid and an optics due to fluorescence, I think it was something like that. If I think that in a matter of five years we will see bombs that combined with a continuous meter, they will automatically provide insulin during the night.Although for an artificial pancreas, literally understood, where the user does not have to do anything, there is much, in my opinion today it is impossible.
No signature configured, update it from user's profile.
I mean this, I can't find exactly where I read it, but San Google has given me this press release.It has a lot to do with a company called Medisense that I bought Medtronic a few years ago.Now I don't have much time, then I will pass and I make a summary patterra translation, that my English does not give so much hehe
No signature configured, update it from user's profile.
:)) :)) It was Sensimed, Medisensor G8 are those optical sensors that are supposed to be ready to launch the market.They are little original with the names hahaha!
